Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-11-13
2007-11-13
Ungar, Susan (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C424S009100, C435S091200
Reexamination Certificate
active
11294621
ABSTRACT:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
REFERENCES:
patent: 25185/92 (1992-09-01), None
Pao et al (PNAS, 2004, 101:13306-13311).
Riley et al (Clinical Cancer Research, 2006, 12:839-844).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Slamon et al. (Science vol. 235, Jan. 1987, pp. 177-182).
Kobayashi et al (New England Journal of Medicine, 2005, 352:786-792).
Tokumo et al (Lung Cancer, 2006, 53:117-121).
Choong et al (Nature Clinical Practice Oncology, 2006, 3:50-57).
Paez et al (Science, 2004, 304:1497-1500).
Lynch et al (New England J of Medicine, 2004, 350:2129-2139).
Cohen et al (Clinical Cancer Research, 2005, 11:8105-8108).
Cappuzzo et al (J Clinical Oncology, 2003, 14:2658-2663).
Riely et al (Clinical Cancer Research, 2006, 12:839-844).
Greulich et al, PIoS Medicine, 2005, 11:1167-1176.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Bowie et al (Science, 1990, 247:1306-1310).
Carlos L. Arteaga et al. (1997) Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with ATP binding site. J. Biol. Chem. 272(37): 23247-54.
Hui-Kuo G. Shu, et al. (1990) Tissue-specific transformation by epidermal growth factor receptor: A single point mutation within the ATP-binding pocket of theerbBproduct increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc. Natl. Acad. Sci. USA 87: 9103-7.
Stephanie Blencke et. al. (2003) Mutation of Threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitor. J. Biol. Chem. 278(17): 15435-40.
Johan F. Vansteenkiste (2004) Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer. Exprt Rev. Anticancer Ther. 4(1): 5-17.
Bell Daphne Winifred
Haber Daniel A.
Janne Pasi Antero
Johnson Bruce E.
Lynch Thomas J.
Dana-Farber Cancer Institute Inc.
Goddard Laura B
Nixon & Peabody LLP
The General Hospital Corporation
Ungar Susan
LandOfFree
Method to determine responsiveness of cancer to epidermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to determine responsiveness of cancer to epidermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to determine responsiveness of cancer to epidermal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808842